Drug-Induced Parkinsonism

Drug Induced Movement Disorders: Second Edition

Volumn , Issue , 2008, Pages 103-139

  Friedman, Joseph H ^a   Trieschmann, Martha E ^a   Fernandez, Hubert H ^b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Bradykinesia; Drug exposure; Drug induced parkinsonism; Prodromal symptoms; Tremor

Indexed keywords

EID: 84890973320     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470753217.ch6     Document Type: Chapter

References (177)

1. Freyhan F. Comments on the biological and psychopathological basis of individual variation in chlorpromazine therapy. Encephale 1957; 45: 913-919.
2. Hornykiewicz O. Parkinsonism induced by dopaminergic antagonists. Adv Neurol 1975 1975; 9: 155-164.
3. Freyhan F. Psychomotility and parkinsonism in treatment with neuroleptic drugs. Arch Neurol Psychiatry 1957; 78: 465-472.
4. Carlsson A. The occurrence, distribution and physiological role of catecholemines in the nervous system. Pharmacol Rev 1959; 11: 490-493.
5. Ehringer H, Hornykiewicz O. Verteilung von noradrenalen und doapmine (3-hydroxytyramine) im gehirn des menschen und ihr berhatten bei erkrankingen des ex-trapyramidalen systems. Klin Wochenschr 1960; 24: 1236-1239.
6. Cotzias G, Woert MV, Schiffer L. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-379.
7. Haase H. Extrapyramidal modification of fine movements: a "condtio sine qua non" of the fundamental therapeutic action of neuroleptic drugs. Rev Can Biol 1961; 20: 425-449.
8. Friedman JH, Max J, Swift R. Idiopathic parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and levodopa. Clin Neuropharmacol 1987; 10: 470-475.
9. Marti-Masso J, Poza J. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998; 13(3): 453-456.
10. Micheli F, Pardal M, Giannaula R, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 1989; 4(2): 139-146.
11. Belforte J, Magarinos-Azcone C, Armando I, Buno W, JH P. Pharmacological involvement of the calcium channel blocker flunarizine in dopamine transmission at the striatum. Parkinsonism Relat Disord 2001; 8(1): 33-40.
12. Hardie R, Lees A. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988; 51: 850-854.
13. Akbostanci M, Atbasoglu E, Balaban H. Tardive dyskinesia, mild drug-induced dyskenisia, and drug-induced parkinsonism: risk factors and topographic distribution. Acta Neurol Belg 1999; 99: 176-181.
14. Group NIoMHPSCCS. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 246-261.
15. Lohr J, Lohr M, Wasli E, et al. Self perception of tardive dyskinesia and neuroleptic induced parkinsonism: a study of clinical correlates. Psychopharmacol Bull 1987; 23: 211-214.
16. Friedman JH. Personal observation.
17. Villeneuve A. The rabbit syndrome: a peculiar extrapyramidal reaction. Can Psychiatr Assoc J 1972;(suppl 2): S69-S72.
18. Hoy J, Alexander B. Rabbit syndrome secondary to risperidone. Pharmacotherapy 2002; 22(4): 513-515.
19. Duvoisin R. Problems in the treatment of parkinsonism. Adv Exp Med Biol 1977; 99: 131-155.
20. Chabolla D, Maraganore D, Ahlskog J, O'Brien P, Rocca W. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota. Mayo Clin Proc 1998; 73: 724-727.
21. Ayd F. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054-1060.
22. Klawans H, Bergen D, Bruyn G. Prolonged drug-induced parkinsonism. Confin Neurol 1973; 35: 368-377.
23. Friedman J, Jennings D, Seibyl J, Marek K. B-CIT SPECT imaging to distinguish drug-induced parkinsonism from idiopathic Parkinson's disease exacerbated by drugs: pilot data, Part I. In 16th Annual Symposia: Movement Disorders, 2002.
24. Hymas N, Lees AJ, Bolton D, et al. The neurology of obsessional slowness. Brain 1991; 114: 2203-2233.
25. Freyhan F. Therapeutic implications of differential effects of new phenothiazine compounds. Am J Psychiatry 1959; 115: 577-585.
26. Medinar C, Kramer M, Kurland A. Biperiden in the treatment of phenothiazine-induced extra-pyramidal reactions. JAMA 1962; 182: 1127-1128.
27. Levinson D, Simpson G, Singh H, et al. Fluphenazine dose, clinical response and ex-trapyramidal symptoms during acute treatment. Am J Psychiatry 1990; 47: 761-769.
28. Bradley P. Psychopharmacology of antipsychotic drugs. In Bradley P, ed. Psychopharmacology and Treatment of Schizophrenia. Oxford, Oxford University Press, 1986, pp. 27-70.
29. Jenner P, Marsden C. Neuroleptic agents: acute and chronic receptor actions. In Howell D, ed. Drugs in Central Nervous System Disorders. New York, Marcel Dekker, 1985, pp. 149-262.
30. Azima H, Ogle W. Effects of largactil in mental syndromes. Can Med Assoc J 1954; 71: 116-121.
31. Kennedy P, Hershon H, McGuire R. Extrapyramidal disorders after prolonged phenoth-iazine therapy. Br J Psychiatry 1971; 118: 509-518.
32. DiMascio A, Demirgian E. Antiparkinson drug overuse. Psychosomatics 1970; 11: 596-601.
33. Fernandez HH, Krupp B, Friedman J. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14 year follow-up. Neurology 2001; 56: 805-807.
34. Rocca W, Bower J, McDonnell S, Peterson B, Maraganore D. Time trends in the incidence of parkinsonism in Olmsted County, Minnesota. Neurology 2001; 57: 462-467.
35. Baldereschi M, Di Carlo A, Rocca W, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. Neurology 2000; 55: 1358-1363.
36. Bower J, Maraganore D, McDonnell S, Rocca W. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52: 1214-1220
37. Rajput A, Offord K, Beard C, Kurland L. Epidemiology of Parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16: 278-282.
38. de Rijk M, Breteler M, Graveland G, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995; 45: 2143-2146.
39. Kessler I. Parkinson's disease in epidemiologic perspective. Adv Neurol 1978; 19: 355-384.
40. Stephen P, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; 2: 1082-1083.
41. Wilson J, MacLennan W. Drug-induced parkinsonism in the elderly. Age Aging 1989; 18: 208-210.
42. Richardson M, Craig T. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. Am J Psychiatry 1982; 139: 341-343.
43. Crane G. Pseudoparkinsonism and tardive dyskinesia. Arch Neurol Psychiatry 1972; 27: 426-430.
44. Kucharski L, Friedman J, Wagner R. An investigation of the co-existence of abnormal involuntary movements, parkinsonism and akathisia in chronic psychiatric patients. Psychopharmacol Bull 1987; 23: 215-217.
45. Inoue F, Vanikowski A. Withdrawal akinesia. J Neurol Neurosurg Psychiatry 1981; 44: 958.
46. Nelli A, Yarden P, Feinberg I. Parkinsonism following neuroleptic withdrawal. Arch Gen Psychiatry 1989; 46: 383-384.
47. Nishimura K, Tsuka M, Horikawa N. Withdrawal-emergent rabbit syndrome during dose reduction of risperidone. Eur Neuropsychopharmacol 2001; 11(4): 323-324.
48. Marsden C, Midham R, Mackay A. Extrapyramidal movement disorders produced by antipsychotic drugs. In: Bradley P (ed) Psychopharmacology and Treatment of Schizophrenia. Oxford, Oxford University Press, 1986, pp. 340-402.
49. Caligiuri M, Lacro J, Jeste D. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychophar-macol 1999; 19: 322-328.
50. Keepers G, Clappison V, Casey D. Initial anticholinergic prophylaxis for neuroleptic induced extrapyramidal syndromes. Arch Gen Psychiatry 1983; 40: 1113-1117.
51. Chakos M, Mayerhoff D, Loebel A, Alvir J, Lieberman J. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992; 28(1): 81-86.
52. Myrianthopoulos N, Kurland A, Kurland L. Hereditary predisposition in drug-induced parkinsonism. Arch Neurol 1962; 6: 19-23.
53. Myrianthopoulos N, Waldrop F, Vincent B. A repeat study of hereditary predisposition to drug-induced parkinsonism. Progr Neurogen 1967; 175: 486-491.
54. Metzen W, Newton J, Steele R, et al. HLA antigens in drug-induced parkinsonism. Mov Disord 1989; 4: 121-128.
55. Knopp W, Fischer R, Kech J, Teitelbaum A. Clinical implications of the relation between taste sensitivity and the appearance of extrapyramidal side effects. Disord Nerv Syst 1966; 27: 729-735.
56. Demars J. Neuromuscular effects of long-term phenothiazine medications, electrocon-vulsive therapy and parkinsonism. J Nerv Ment Disord 1966; 143: 73-79.
57. Luckins D, Jackman H, Meltzer H. Lateral ventricular size and drug-induced parkinsonism. Psychiatr Res 1983; 9: 9-16.
58. Tune L, Coyle J. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 1981; 75: 9-15.
59. Hansen L, Larsen N, Vestergard P. Plasma levels of perphenazine related to development of extrapyramidal effects. Psychopharmacology 1981; 74: 306-309.
60. Alpert M, Diamond F, Kesselman M. Correlation between extrapyramidal and therapeutic effects of neuroleptics. Compar Psychiatry 1977; 18: 333-336.
61. Simpson G, Kunz-Bartholini E. Relationship of individual tolerance and behavior in phe-nothiazine produced extrapyramidal system disturbance. Disord Nerv Syst 1968; 29: 269274.
62. Baldessarini R, Tarazi F. Drugs and the treatment of psychiatric disorders: psychosis and mania. In Hardman J, Limbird L (eds) Goodman and Gilman's The Pharmacologic Basis of Therapeutics. New York, McGraw Hill, 2002, pp. 485-520.
63. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15(2): 201-211.
64. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999; 52: 782-785.
65. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994; 344: 681.
66. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56(12): 556-559.
67. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic, a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
68. Friedman J, Fernandez H. Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol 2002; 15: 156-170.
69. Group TFCPS. Clozapine in drug-induced psychosis n Parkinson's disease. Lancet 1999; 353: 2041-2042.
70. Marder S, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6): 825-835.
71. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15 (suppl 1): 36S-44S.
72. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1996; 166(6): 712-726.
73. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman J. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998; 59(2): 69-75.
74. Simpson G, Lindenmayer J-P. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1996; 17: 194-201.
75. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-955.
76. Steinwachs A, Grohmann R, Pedrosa F, Ruther E, Schwerdtner I. Two cases of olanzapine-induced reversible neutropenia. Pharmocopsychiatry 1999; 32(4): 154-156.
77. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000; 12(3): 364-369.
78. Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997; 12(4): 1241-1254.
79. Leopold N. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000; 15(2): 301-304.
80. Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000; 15(6): 1230-1237
81. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease [letter]. Mov Disord 2001; 17(1): 221-225.
82. Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a doubleblind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-167.
83. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14(2): 111-123.
84. Beasley CM, Hamilton S, Crawford AM, Dellva MA, Tollefson G, Tran P, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7: 125-137.
85. Tollefson G, Beasley CM, Tran P, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154(4): 457-465.
86. Tollefson G, Kuntz AJ. Review of recent clinical studies with olanzapine. Br J Psychiatry 1999; 174 (suppl 37): 30-35.
87. Tran P, Hamilton S, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17(5): 407-418.
88. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085-1087.
89. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine. Neurology 2000; 55: 789-794.
90. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open-label pilot trial. Clin Neuropharmocol 1998; 21: 285-288.
91. Friedman JH, Goldstein S. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1998; 50: 1195-1196.
92. Wirshing D, Spellberg B, Erhart S, Marder S, Wirshing W. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44(8): 778-783.
93. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999; 14: 1014-1016.
94. Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000; 55: 795-799.
95. Caroff SN, Mann SC, Campbell EC, Sullivan K. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63 (suppl 4): 12-19.
96. Breier A, Sutton V, Feldman P, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52(5): 438.
97. Ondo W, Levy J, Vuong K, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002; 17(5): 1031-1035.
98. Small J, Hirsch S, Arvantis L, et al. Quetiapine in patients with schizophrenia: a high and low dose double blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549-557.
99. Arvantis L, Miller B, Group tSTS. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbations of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-246.
100. Keck PJ, Buffenstien A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173-184.
101. Daniel DG, Zimbroff DL, Potkin S, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20(5): 491-505.
102. Keck PJ, Reeves K, Harrigan EP, Group tZS. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol 2001; 21(1): 27-35.
103. Tandon R, Harrigan E, Zorn S. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159-177.
104. Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R. A 28-week comparison of ziprasi-done and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002; 63(6): 516-523.
105. Weiden PJ, Iqbal N, Mendelowitz AJ, Tandon R, Zibroff DL, Ross R. Best clinical experience with ziprasidone: update after one year experience. J Psychiat Pract 2002; 8(2): 81-97.
106. Davis R, Markham A. Ziprasidone. CNS Drugs 1997; 8(2): 153-162.
107. Shopsin B, Gershon S. Cogwheel rigidity related to lithium maintenance. Am J Psychiatry 1975; 132: 536-538.
108. Ghadirian A, Annable L, Belanger M, Chouinard G. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 1996; 57(1): 22-28.
109. Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47: 626-635.
110. Power C, Blume W, Young G. Reversible parkinsonism associated with valproate therapy [abstract]. Neurology 1990; 40(suppl 1): 139.
111. Iijima M. Valproate-induced parkinsonism in a demented elderly patient. J Clin Psychiatry 2002; 63(1): 75
112. Yatham L, Liddle P, Lam R, et al. PET study of the effects of valproate on dopamine D2 receptors in neuroleptic-and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry 2002; 159: 1718-1723.
113. Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine-and flunarizine-induced parkinsonism. Mov Disord 1997; 12(1): 107-110.
114. Leo R. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449-454.
115. Schechter D, Nunes E. Reversible parkinsonism in a 90-year-old man taking sertraline. J Clin Psychiatry 1997; 58(6): 275.
116. Gerber P, Lynd L. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32(6): 692-698.
117. Jimenez-Jimenez F, Tejeiro J, Martinez-Junquera G, et al. Parkinsonism exacerbated by paroxetine [Letter]. Neurology 1994; 44: 2406.
118. Jansen ENH. Increase of parkinsonism disability after fluoxetine medication. Neurology 1993; 43: 211-213.
119. Gonul A, Aksu M. SSRI-induced parkinsonism may be an early sign of future Parkinson's disease. J Clin Psychiatry 1999; 60(6): 410.
120. Pina Latorre M, Modrego P, Rodilla F, Catalan C, Calvo M. Parkinsonism and Parkinson's disease associated with long-term administration of sertraline. J Clin Pharmacol Ther 2001; 26(2): 111-112.
121. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001; 24(4): 221-227.
122. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000; 55(8): 1216-1218.
123. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani C, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000; 15(5): 986-989.
124. Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen parkinson's disease? A retrospective case series. Mov Disord 1999; 14(1): 155.
125. Yamato H, Kannari K, Shen H, Suda T, Matsunaga M. Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport 2001; 12(6): 1123-1126.
126. Leo R, Lichter D, Hershey L. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol 1995; 8: 231-233.
127. Reches A, Burke R, Kuker C, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors. J Pharmacol Exp Ther 1983; 225: 515-521.
128. Snyder S, Banerjee S, Yamaura H, Greenberg D. Drugs, neurotransmitters and schizophrenia. Science 1974; 184: 1243-1253.
129. Mash D. Dopamine receptor diversity. In Factor SA, Weiner WJ (eds) Parkinson's Disease: Diagnosis and Clinical Management. New York, Demos Medical Publishing, 2002, pp. 233-241.
130. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001; 158(3): 360-369.
131. Meltzer H, Matsubara S, Lee J. The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-392.
132. Ichikawa J, Ishii H, Bonaccorso S, Fowler W, O'Laughlin I, Meltzer H. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76: 1521-1531.
133. Meltzer H. Action of atypical antipsychotics [Letter]. Am J Psychiatry 2002; 159(1): 153-154.
134. Rabey J, Burns R. Neurochemistry. In Factor SA, Weiner WJ (eds) Parkinson's Disease: Diagnosis and Clinical Management. New York, Demos Medical Publishing, 2002, pp. 195-209.
135. Fjalland B, Christensen A, Hyttel J. Peripheral and central muscarinic receptor affinity and psychotropic drugs. Naunyn-Schmiedebergs' Arch Pharmacol 1977; 301: 5-12.
136. Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984; 45: 331-336.
137. Friedman JH. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2003; 48: 62.
138. Mindham R. Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. Br J Clin Pharmacol 1976; 3(suppl): 395-400.
139. Parkinson Study Group. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46: 1052-1060.
140. Simpson G, Amuso D, Blair J, Farhas T. Phenothiazine produces extrapyramidal disturbance. Arch Gen Psychiatry 1964; 10: 127-136.
141. DiMascio A, Bernardo D, Greenblatt D, Marder J. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599-602.
142. Mindham R, Gaind R, Anstee B, Rimmer L. Comparison of amantadine, orphenadrine and placebo in drug-induced parkinsonism. Psychol Med 1972; 2: 406-443.
143. Simpson G. Controlled studies of antiparkinsonism agents in the treatment of extrapyramidal syndromes. Acta Psychiat Scand 1970; 212: 44-51.
144. Kelly J, Zimmerman R, Abuzzahab F, Schieve B. A double blind study of amantadine HCl versus benztropine mesylate in drug-induced parkinsonism. Pharmacology 1974; 12: 65-73.
145. Adler C. Amantadine and Anticholinergics. In Factor SA, Weiner WJ (eds) Parkinson's Disease: Diagnosis and Clinical Management. New York, Demos Medical Publishing, 2002, pp. 357-364.
146. Greenblatt D, DiMascio A, Harmatz J, et al. Pharamacokinetics and clinical effects of amantadine in drug-induced extrapyramidal syndromes. J Clin Pharmacology 1977; 17: 704-708.
147. Stenson R, Donlon P, Mayer J. Comparison of benztropine and amantadine in neuroleptic-induced extrapyramidal syndromes. Compar Psychiatry 1976; 17: 762-768.
148. Pacific G, Nardini M, Ferrani P, et al. Effect of amantadine on drug-induced parkinsonism: relationship between plasma levels and effect. Br J Clin Pharmacol 1976; 3: 883-889.
149. Carlson A. The occurrence, distribution, and physiologic role of catecholamines in the nervous system. Pharmacol Res 1959; 11: 490-493.
150. Bruno A, Bruno S. Effects of levodopa on pharmacological parkinsonism. Acta Psychiat Scand 1966; 42: 264-271.
151. Angrist B, Sathanathan G, Gershon S. Behavioral effects of levodopa in schizophrenic patients. Psychopharmacologica (Berl) 1973; 31: 1-12.
152. Yaryura-Tobias, Wolpert A, Dana L, Malis S. Action of L-dopa on drug-induced ex-trapyramidal syndromes. Disord Nerv Syst 1973; 31: 60-63.
153. Inanga K, Inouye K, Tachibana H, et al. Effect of levodopa in schizophrenia. Folia Psychiatr Neurol Jpn 1972; 26: 145-157.
154. Balldin J, Eden S, Granerus A. Electroconvulsive therapy in Parkinson's syndrome with "on-off" phenomenon. J Neur Transm 1980; 47: 11-21.
155. Andersen K, Balldin J, Gottfries C. Double Blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand 1987; 76: 191-199.
156. Moellentine C, T R, Ahlskog J, Harmsen W, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 1998; 10(2): 187-193.
157. Fall P, Granerus A. Maintenance ECT in Parkinson's disease. J Neur Transm 1999; 106 (7-8): 737-741.
158. Wengel S, Burke W, Pfeiffer R, Roccaforte W, Paige S. Maintenance electroconvulsive therapy for intractable Parkinson's disease. Am J Geriatr Psychiatry 1998; 6(3): 263-269.
159. Goswami U, Dutta S, Jurivilla K. Electroconvulsive therapy in neuroleptic-induced parkinsonism. Biol Psychiatry 1989; 26: 234-238.
160. Mukherjee S, Debsikdar V. Absence of neuroleptic-induced parkinsonism in psychotic patients receiving adjunctive electroconvulsive therapy. Convul Ther 1994; 10(1): 53-58.
161. Hanin B, Lerner Y, Srour N. An unusual effect of ECT on drug-induced parkinsonism and tardive dystonia. Convul Ther 1995; 11(4): 271-274.
162. Metzer W, Paige S, Newton J. Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor. Mov Disord 1993; 8(1): 43-36.
163. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58: 318-322.
164. Levine J, Chengappa K. Second thoughts about clozapine as a treatment for neuroleptic-induced akathisia [Letter]. J Clin Psychiatry 1998; 59(4): 195.
165. Fann W, Lake C. On the coexistence of parkinsonism and tardive dyskinesia. Dis Nerv Syst 1974; 35: 324-326.
166. DeFraites E, Davis K, Berger P. Coexisting tardive dykinesia and parkinsonism: a cast report. Biol Psychiatry 1977; 12: 267-272.
167. Fahn S, Mayeux R. Unilateral parkinson's disease and contralateral tardive dyskinesia: a unique case with successful therapy that may explain the pathophysiology of these two disorders. J Neur Transm 1980; 16: 179-185.
168. Jankovic J, Casabona J. Dyskinesia and parkinsonism. Clin Neuropharmacol 1987; 10: 511-521.
169. Honlon T, Shoenrich C, Freinek W. Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients. Psychopharmacologica (Berl) 1966; 9: 328-329.
170. Chien C, DiMascio A, Cole J. Antiparkinson agents and depot phenothiazine. Am J Psychiatry 1974; 131: 86-90.
171. McGeer P, Bouling J, Gibson W, Foulkes R. Drug-induced extrapyramidal treatment with dyphenhydramine hydrochloride and dihydroxyphenylalanine reactions. JAMA 1961; 177: 166-170.
172. Stratos N, Phillips R, Walker P, Sandifer M. A study of drug-induced parkinsonism. Dis Nerv Syst 1963; 24: 180-181.
173. Cahan R, Parrish D. Reversibility of drug-induced parkinsonism. Am J Psychiatry 1960; 116: 1022-1023.
174. Manos N, Ghiouzepas J, Logothetis J. The need for continuous anti-parkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. Am J Psychiatry 1981; 138: 184-188.
175. Grove L, Cramer J. Benzhexol and side effects with long lasting fluphenazine therapy. Br Med J 1972; 1: 276-279.
176. Mandel W, Claffe B, Margolis L. Recurrent thioperazine induced extrapyramidal reaction following placebo substitutions for maintenance antiparkinsonian drugs. Am J Psychiatry 1962; 118: 351-352.
177. St. Jean A, Donald M, Ban T. Interchangeability of antiparkinsonian medication. Am J Psychiatry 1964; 120: 1189-1190.